CN119156210A - 纯形式的结晶阿替卡普兰 - Google Patents

纯形式的结晶阿替卡普兰 Download PDF

Info

Publication number
CN119156210A
CN119156210A CN202380038807.1A CN202380038807A CN119156210A CN 119156210 A CN119156210 A CN 119156210A CN 202380038807 A CN202380038807 A CN 202380038807A CN 119156210 A CN119156210 A CN 119156210A
Authority
CN
China
Prior art keywords
composition
crystalline form
alteplerian
chemically
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380038807.1A
Other languages
English (en)
Chinese (zh)
Inventor
R·瑟蒙
M·施密特
V·波波瓦
A·萨维茨
R·梅尔科特
W·C·德雷维茨
S·戈帕尔
D·彭伯顿
C·拉吉谢蒂
I·克日奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CN119156210A publication Critical patent/CN119156210A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380038807.1A 2022-03-07 2023-03-06 纯形式的结晶阿替卡普兰 Pending CN119156210A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317483P 2022-03-07 2022-03-07
US63/317483 2022-03-07
PCT/IB2023/052082 WO2023170547A1 (en) 2022-03-07 2023-03-06 Pure forms of crystalline aticaprant

Publications (1)

Publication Number Publication Date
CN119156210A true CN119156210A (zh) 2024-12-17

Family

ID=85979414

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380038807.1A Pending CN119156210A (zh) 2022-03-07 2023-03-06 纯形式的结晶阿替卡普兰

Country Status (15)

Country Link
US (2) US20230348377A1 (https=)
EP (1) EP4489748A1 (https=)
JP (1) JP2025508071A (https=)
KR (1) KR20240158951A (https=)
CN (1) CN119156210A (https=)
AU (1) AU2023231493A1 (https=)
CA (1) CA3254503A1 (https=)
CL (1) CL2024002643A1 (https=)
CO (1) CO2024012457A2 (https=)
IL (1) IL315411A (https=)
JO (1) JOP20240195A1 (https=)
MX (1) MX2024010978A (https=)
PE (1) PE20242109A1 (https=)
TW (1) TW202345795A (https=)
WO (1) WO2023170547A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder
CN117903050B (zh) * 2024-03-15 2024-05-17 中国药科大学 阿立哌唑共晶及其药物组合物和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5345637B2 (ja) * 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト
US10316021B2 (en) * 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
PH12023552963A1 (en) * 2021-05-04 2024-03-11 Janssen Pharmaceuticals Inc Compositions and methods for the treatment of depression

Also Published As

Publication number Publication date
KR20240158951A (ko) 2024-11-05
EP4489748A1 (en) 2025-01-15
JOP20240195A1 (ar) 2024-09-05
JP2025508071A (ja) 2025-03-21
CL2024002643A1 (es) 2025-01-24
AU2023231493A1 (en) 2024-10-24
TW202345795A (zh) 2023-12-01
US20250326714A1 (en) 2025-10-23
WO2023170547A1 (en) 2023-09-14
MX2024010978A (es) 2024-12-06
CO2024012457A2 (es) 2024-09-30
PE20242109A1 (es) 2024-10-28
IL315411A (en) 2024-11-01
CA3254503A1 (en) 2023-09-14
US20230348377A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
CN119156210A (zh) 纯形式的结晶阿替卡普兰
CN115154470B (zh) 使用食欲素-2受体拮抗剂治疗抑郁症的方法
CN113271936A (zh) 治疗神经和精神疾病的方法
CZ20014625A3 (cs) Vysoce selektivní inhibitory opětovného příjmu norepinefrinu a způsoby jejich pouľití
AU2015355226B2 (en) Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
WO2012118562A1 (en) Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US20110070319A1 (en) Bifeprunox doses for treating schizophrenia
CN119156202A (zh) 包含阿替卡普兰的组合物
AU2003230683B2 (en) Method for treating cognitive disorders
AU2017321016B2 (en) Compound for use in the treatment of neurogenic orthostatic hypotension
CN119156211A (zh) 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
CN107108560B (zh) 化合物、组合物及其方法
CN121969364A (zh) 用于在治疗重性抑郁障碍中使用的包含阿替卡普兰的组合物
CA2763551A1 (en) Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
WO2024158972A1 (en) Methods and compositions for preventing the progression of diabetic retinopathy and related conditions
AU2005215790A1 (en) Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites
WO2024196957A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
TW202521119A (zh) 用於投與特定vmat2抑制劑之方法
WO2012129262A1 (en) Treatment of attention deficit/hyperactivity disease
HK40057761A (en) Methods of treating neurological and psychiatric disorders
NZ732033B2 (en) Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination